Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.41 |
| ▸ | CES2 | O00748 | 1/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.38 |
| ▸ | PDE2A | O00408 | 1/20 | 0.37 |
| ▸ | ACP3 | P15309 | 1/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.36 |
| ▸ | AURKA | O14965 | 1/20 | 0.36 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.36 |
| ▸ | DAO | P14920 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5206641 | 0.82 | PNMT (0.50) | PNMTALDH1A1L3MBTL1KCNA5CES2 | |
| SCHEMBL5203460 | 0.82 | PNMT (0.40) | PNMTALDH1A1L3MBTL1KCNA5CES2 | |
| SCHEMBL5201101 | 0.79 | ALDH1A1 (0.39) | PNMTALDH1A1L3MBTL1KCNA5CES2 | |
| SCHEMBL17465593 | 0.78 | CES2 (0.50) | PNMTALDH1A1CES2ACP3SLC6A2 | |
| SCHEMBL2538654 | 0.78 | CES2 (0.50) | PNMTALDH1A1CES2ACP3SLC6A2 | |
| SCHEMBL4524501 | 0.78 | CES2 (0.50) | PNMTALDH1A1CES2ACP3SLC6A2 | |
| SCHEMBL29600944 | 0.78 | CES2 (0.50) | PNMTALDH1A1CES2ACP3SLC6A2 | |
| SCHEMBL7502772 | 0.74 | PNMT (0.42) | PNMTALDH1A1L3MBTL1KCNA5CES2 | |
| SCHEMBL5201104 | 0.72 | EPHX1 (0.40) | PNMTALDH1A1L3MBTL1KCNA5CES2 | |
| SCHEMBL18925489 | 0.71 | CES2 (0.44) | PNMTCES2ACP3SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1414443-B1 | BENZIMIDAZO 4,5-f|ISOQUINOLINONE DERIVATIVES | MERCK & CO INC (US) | 2006-11-15 | — | — | EP | disclosed |
| EP-1414443-A4 | BENZIMIDAZO 4,5-f]ISOQUINOLINONE DERIVATIVES | MERCK & CO INC (US) | 2005-05-11 | — | — | EP | disclosed |
| US-6852727-B2 | Benzimisazo[4,5-f]isoquinolinone derivatives | MERCK & CO., INC. (US) | 2005-02-08 | — | — | US | disclosed |
| US-20040176601-A1 | Benzimisazo[4,5-f]isoquinolinone derivatives | MERCK SHARP & DOHME LLC | 2004-09-09 | — | — | US | disclosed |
| EP-1414443-A1 | BENZIMIDAZO 4,5-f]ISOQUINOLINONE DERIVATIVES | Merck & Co., Inc. (US) | 2004-05-06 | — | — | EP | disclosed |
| WO-2003011285-A1 | BENZIMIDAZO[4,5-f]ISOQUINOLINONE DERIVATIVES | MERCK & CO., INC. (US) | 2003-02-13 | — | — | WO | disclosed |
| US-6291457-B1 | SUBSTITUTED IMIDAZOLE COMPOUNDS | MERCK & CO., INC. | 2001-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176601-A1 | Benzimisazo[4,5-f]isoquinolinone derivatives | JAK1, JAK3, JAK2 | PNMT 2772/4885ALDH1A1 2321/4885L3MBTL1 2112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.